The safety and tolerability of rotigotine transdermal system over a 6-year period in patients with early-stage Parkinson's disease

Journal of Neural Transmission

Volumn 120, Issue 9, 2013, Pages 1321-1329

  Giladi, Nir ^a   Boroojerdi, Babak ^b   Surmann, Erwin ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b UCB PHARMA   (Belgium)

Author keywords

Dyskinesia; Levodopa; Long term; Parkinson's disease; Rotigotine transdermal system; Safety

Indexed keywords

BENSERAZIDE; CARBIDOPA; DOPAMINE RECEPTOR AFFECTING AGENT; LEVODOPA; ROPINIROLE; ROTIGOTINE;

ADJUVANT THERAPY; ADULT; AGED; APPLICATION SITE REACTION; ARTICLE; BACKACHE; COMPULSION; CONTROLLED STUDY; DEPRESSION; DISEASE DURATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; DYSKINESIA; FALLING; FEMALE; HEART INFARCTION; HUMAN; HYPERTENSION; IMPULSIVENESS; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; OPEN STUDY; OPTIMAL DRUG DOSE; OSTEOARTHRITIS; PARKINSON DISEASE; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; UNIFIED PARKINSON DISEASE RATING SCALE;

ADOLESCENT; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DYSKINESIA, DRUG-INDUCED; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TETRAHYDRONAPHTHALENES; THIOPHENES; TRANSDERMAL PATCH; TREATMENT OUTCOME;

EID: 84883451122     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-013-1001-5     Document Type: Article

References (19)

1. Elmer LW, Surmann E, Boroojerdi B, Jankovic J (2012) Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson's disease: a prospective, open-label extension study. Parkinsonism Relat Disord 18:488-493. doi: 10.1016/j.parkreldis.2012.01.008
2. Elshoff JP, Braun M, Andreas JO, Middle M, Cawello W (2012) Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies. Clin Ther 34:966-978. doi: 10.1016/j.clinthera.2012.02.008
3. Factor SA (2008) Current status of symptomatic medical therapy in Parkinson's disease. Neurotherapeutics 5:164-180
4. Giladi N, Boroojerdi B, Korczyn AD, Burn DJ, Clarke CE, Schapira AH (2007) Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 22:2398-2404
5. Giladi N, Fichtner A, Poewe W, Boroojerdi B (2010) Rotigotine transdermal system for control of early morning motor impairment and sleep disturbances in patients with Parkinson's disease. J Neural Transm 117:1395-1399
6. Hauser RA, Rascol O, Korczyn AD, Jon Stoessl A, Watts RL, Poewe W, De Deyn PP, Lang AE (2007) Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 22:2409-2417
7. Holloway RG, Shoulson I, Fahn S et al (2004) Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 61:1044-1053
8. Jankovic J (2005) Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov Disord 20(Suppl 11):S11-S16
9. Jankovic J, Aguilar LG (2008) Current approaches to the treatment of Parkinson's disease. Neuropsychiatr Dis Treat 4:743-757
10. Jankovic J, Watts RL, Martin W, Boroojerdi B (2007) Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol 64:676-682
11. LeWitt PA, Lyons KE, Pahwa R (2007) Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology 68:1262-1267
12. Parkinson Study Group (2009) Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol 66:563-570
13. Poewe W (2006) The natural history of Parkinson's disease. J Neurol 253(Suppl 7):VII2-VII6
14. Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E, Rupp M, Boroojerdi B (2007) Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 6:513-520
15. Poewe W, Antonini A, Zijlmans JC, Burkhard PR, Vingerhoets F (2010) Levodopa in the treatment of Parkinson's disease: an old drug still going strong. Clin Interv Aging 5:229-238
16. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 342:1484-1491
17. Scheller D, Ullmer C, Berkels R, Gwarek M, Lübbert H (2009) The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease. Naunyn Schmiedebergs Arch Pharmacol 379:73-86
18. Trenkwalder C, Kies B, Rudzinska M et al (2011) Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 26:90-99
19. Watts RL, Jankovic J, Waters C, Rajput A, Boroojerdi B, Rao J (2007) Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 68:272-276